Related Experiment Video

Updated: Jun 5, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR-TKIs Resistance

Jin Tian1, Zhiqi Shi2, Lili Zhao1

  • 1Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, China.

The Clinical Respiratory Journal
|December 4, 2024
PubMed

Insights

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard for EGFR-mutated non-small cell lung cancer (NSCLC). This review explores immune checkpoint inhibitors (ICIs) as a treatment option following EGFR-TKI resistance.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a primary treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
  • Acquired resistance to EGFR-TKIs is a significant clinical challenge in advanced NSCLC treatment.
  • Immune checkpoint inhibitors (ICIs) represent a novel therapeutic strategy for advanced NSCLC, particularly in patients lacking targetable molecular alterations.

Purpose of the Study:

  • To review the current landscape of immunotherapy in non-small cell lung cancer patients who have developed resistance to EGFR-TKIs.
  • To explore the efficacy and application of various immunotherapy strategies, including monotherapy and combination treatments.

Main Methods:

  • Literature review of studies investigating immune checkpoint inhibitors (ICIs) in the context of EGFR-TKI resistance in NSCLC.
  • Analysis of current treatment approaches, including monotherapy, combination with EGFR-TKIs, chemotherapy, and antiangiogenic agents.

Main Results:

  • EGFR-TKI resistance remains a critical issue in advanced NSCLC management.
  • Immune checkpoint inhibitors (ICIs) show potential efficacy in NSCLC patients with acquired resistance to EGFR-TKIs.
  • Combination therapies involving ICIs with other agents are being explored to overcome resistance and improve outcomes.

Conclusions:

  • Immunotherapy, particularly immune checkpoint inhibitors (ICIs), offers a promising avenue for patients with EGFR-TKI-resistant non-small cell lung cancer (NSCLC).
  • Further research into combination strategies is crucial for optimizing treatment efficacy and managing resistance mechanisms in advanced NSCLC.
Keywords:
EGFR‐TKIs resistanceepidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI)immune checkpoint inhibitorsimmunotherapynon‐small cell lung cancer (NSCLC)

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K